Navigation Links
Safety and immunogenicity of 2 doses of the HPV-16/18 AS04 adjuvanted vaccine Cervarix
Date:3/28/2014

A recent study in the journal Human Vaccines & Immunotherapeutics, showed that two doses of the HPV-16/18 AS04-adjuvanted vaccine Cervarix (GlaxoSmithKline) are non-inferior to three-doses in the current schedule.

Since high coverage and compliance rates can be difficult to achieve with the current three-dose HPV vaccineregimen, several studies have looked at the possibility of reducing the number of doses. Proof-of-principle that a two-dose schedule can provide sufficient protection against cervical cancer came initially from a study performed in Costa Rica in 2011. Since then, several countries have considered switching to a two-dose schedule or have already done so. The European Commission recently granted marketing authorization for Cervarix as a two-dose schedule for girls aged 9-14 years, and outside of the EU, the Cervarix two-dose schedule is approved in more than ten countries, including Panama, Guatemala, Honduras, El Salvador, Haiti, Suriname, Chile, Guyana, Nigeria, Ghana, Pakistan, and Bangladesh.

The randomized, partially-blinded Phase I/II clinical trial evaluated the immunogenicity and safety of two doses of the licensed formulation of Cervarix (20 g each of HPV-16 and HPV-18 L1 VLPs, ,20/20') or an alternative formulation (40 g of each HPV-16 and HPV-18 VLPs; ,40/40') in different age groups, compared with the standard three-dose schedule of the licensed formulation. Healthy females (age stratified: 9-14, 15-19, 20-25 years) were randomized to receive two doses of vaccine at months 0 and 6, or three doses of the vaccine at months 0, 1, and 6.

The trial was initiated in 2007 and conducted at 21 centers in Canada and Germany. Results from 24 months of analysis were previously published in HV&I, and the current study presents results from 48 months of analysis. Since the two-dose 40/40 formulation gave no added benefit, the current study focused on data for the two-dose 20/20 formulation in girls aged 9-14 years and the standard three-dose 20/20 schedule in women aged 15-19 years.

The researchers reported that all initially seronegative subjects seroconverted for HPV-16 and HPV-18 antibodies and remained seropositive up to 48 months. The kinetics of HPV-16, -18, -31, and -45 antibody responses were similar for both groups, and the HPV-16 and -18 geometric mean antibody titers were substantially higher than titers following natural infection. The vaccine had a clinically acceptable safety profile in both groups. In summary, antibody responses to a two-dose schedule of the licensed vaccine formulation in girls aged 9-14 years appeared comparable to the standard three-dose schedule in women aged 15-19 years for up to four years after first vaccination.

These results show that a two-dose schedule should confer a similar level of protection against HPV infections and subsequent development of cervical lesions and cancer as the current three-dose schedule. A two-dose schedule obviously would be more convenient for physicians and patients, and could help reduce associated costs. The authors think that these benefits could facilitate the implementation of HPV immunization programs in low-income countries, as well as improve the relatively low vaccine coverage and series completion rates observed in some developed countries.

"Compliance has been a major challenge for HPV vaccination. These data reinforce the value of the two-dose schedule and should lead to increased utilization of this vaccine, with consequent decreases in morbidity and mortality from cervical cancer," said Dr. Ronald Ellis, Editor-in-Chief of Human Vaccines & Immunotherapeutics.


'/>"/>
Contact: Andrew Thompson
andrew@landesbioscience.com
Landes Bioscience
Source:Eurekalert

Related medicine news :

1. Food Safety Considerations for Innovative Nutrition Solutions
2. Hospital food safety measures reduce risk of contaminated hospital food
3. Does the bodys immune response to viral vector delivery systems affect the safety or efficacy of gene therapy?
4. Safety Management Systems Offering New Internationally Approved-courses
5. Safety Training Seminars is Proud to Announce the Opening of an American Heart Association BLS, CPR, & First-aid Certification Training School in Vallejo, Solano County
6. Rf Safe Launches Social Deal Savings On Smart Phone Radiation Safety Accessories
7. Etymotic Creates “Safety Earphones” For High Noise Environments
8. Former Nuclear-Powered Submarine Captain Advises LifeWings on Patient Safety
9. Electrical Safety Devices & Accessories Procurement Research Report Now Available from IBISWorld
10. Atlantic Neurosurgical Specialists (ANS) Offers Tips On Practicing Sports Safety During Winter Team Sports
11. InventHelp Inventors Develop Improved Safety Belt (BGF-692)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... , ... October 13, 2017 , ... While it’s often ... a problem. Fortunately, an inventor from Austin, Texas, has identified a solution. , She ... in darkness or restricted lighting. As such, it eliminates the need to turn on ...
(Date:10/13/2017)... QUEENS, N.Y (PRWEB) , ... October 13, 2017 , ... ... recently became a member of ElderCounsel, a national organization of elder law and special ... constantly changing laws and rules. It also provides a forum to network with elder ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Global Healthcare ... scenic Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare ... activity. The fun run is geared towards children of all ages; it is ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “America On ... Christian identity. “America On The Brink” is the creation of published author, William ... several great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one ... an innovative new design of the shoulder pad. The shoulder pad provides optimal ... controlling your pain while using cold therapy. By utilizing ice and water that is ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... -- Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today provided an ... Puerto Rico , where the company ... Following a comprehensive onsite assessment, ... damage, temporary loss of power and minimal water damage ... operations have resumed, and the company expects to return ...
(Date:10/5/2017)... , Oct. 5, 2017  In response ... of Oral and Maxillofacial Surgeons (AAOMS) released prescribing ... – to be used as a first-line therapy ... Recognizing the ... AAOMS White Paper "Opioid Prescribing: Acute and Postoperative ...
(Date:10/2/2017)... , Oct. 2, 2017 Diplomat Pharmacy, Inc. ... Day Software and Consulting, LLC , and named its ... Software, based in Tennessee , will ... Day expands EnvoyHealth,s service offerings for health care partners ... "In an interoperable world, ...
Breaking Medicine Technology: